Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of migraine in the 12 months prior to screen~* 4-14 days per month of migraine symptoms~* \>=80% diary compliance during the Baseline period~* Failure of previous migraine prophylactic treatments~Exclusion Criteria:~* \>50 years old at migraine onset~* Pregnant or nursing~* History of cluster or hemiplegic headache~* Evidence of seizure or psychiatric disorder~* Score of over 19 on Beck Depression Inventory-2~* Active chronic pain syndrome~* Cardiac or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo DB (Type: PLACEBO_COMPARATOR): Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
- AMG334 140 mg DB (Type: EXPERIMENTAL): AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
- AMG334 140 mg DB cont on AMG334 140 mg (Type: EXPERIMENTAL): AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
- Placebo in DB to AMG334 140 mg (Type: EXPERIMENTAL): Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch

Based on this trial design, predict the completion outcome and termination type (if applicable).